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Background: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are approved for patients with
recurrent non-small cell lung cancer (NSCLC). However, the efficacy of EGFR-TKIs in NSCLC therapy is limited by
primary and acquired resistance. Recent studies have revealed that long non-coding RNAs (LncRNA) may be
involved in EGFR-TKI resistance. Therefore, a better understanding of the interactive mechanisms underlying
LncRNA-mediated EGFR-TKIs resistance may help us to improve clinical response rates.
Method: To investigate the expression of growth arrest-specific 5 (GAS5) in lung adenocarcinoma, we performed
real-time reverse-transcriptase polymerase chain reaction. The correlation between GAS5 expression levels and the
samples’ clinicopathological features was also analyzed. Primary resistance to EGFR-TKIs was identified in the human
lung adenocarcinoma cell line A549. Plasmid vectors were used to overexpress GAS5 in A549 cells. MTT (3-(4,5-
dimethylthiazol-2-Yl)-2,5-diphenyltetrazolium bromide) colony formation assays and EdU (5-ethynyl-2’-deoxyuridine)
assays were used to assess cell proliferation, and flow-cytometric analysis was used to evaluate the apoptosis rate.
The expression levels of our target proteins, namely, EGFR, p-EGFR, ERK, p-ERK, Akt, p-Akt, IGF-1R (insulin-like growth
factor 1 receptor), and p-IGF-1R, were analyzed by western blotting. A549 cells transfected with pcDNA-GAS5 were
injected into nude mice. The transplanted mice were treated with gefitinib to study the effect of GAS5 on the
resistance to EGFR-TKIs in vivo.
Results: Our results showed that GAS5 was significantly downregulated in lung adenocarcinoma tissues compared
with the paired adjacent non-tumorous tissue samples. Furthermore, lower GAS5 expression levels were associated
with larger tumor sizes, poor tumor differentiation, and advanced pathological stages. However, GAS5 was almost
equally expressed between benign tumors compared with the adjacent normal tissues. GAS5 was also
overexpressed in EGFR-TKI sensitive cell lines compared with the resistant cell line. Using MTT, EdU incorporation,
and colony formation assays, we showed that GAS5-expressing A549 cells displayed an elevated level of cell death.
In addition to its pro-apoptotic effect in the A549 cell line, GAS5 overexpression also suppressed the growth of
A549-derived tumors in nude mice treated with gefitinib. GAS5 overexpression was inversely correlated with the
expression of the EGFR pathway and IGF-1R proteins.
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Conclusions: Collectively, our results indicated that GAS5 LncRNA may represent a potential biomarker for the
diagnosis of lung adenocarcinoma and that GAS5 might play a novel role in the development of the resistance to
gefitinib, which could be reversed by overexpressing GAS5.
Keywords: NSCLC, Gefitinib resistance, GAS5, IGF-1RIntroduction
Lung cancer continues to be one of the leading causes of
cancer-related mortality worldwide accounting for 15%
of all cancer diagnoses, and its incidence is increasing
[1]. Lung adenocarcinoma is the major subtype of non-
small cell lung cancer and is usually diagnosed at an ad-
vanced stage; therefore, patients miss the opportunity to
receive surgery, which remains among the best treat-
ments to date [2]. However, the promising benefits of
epidermal growth factor receptor-tyrosine kinase inhibi-
tors (EGFR-TKIs) have been clearly observed [3,4].
EGFR-TKIs are considered to be the standard first-line
treatment for patients with advanced NSCLC harboring
activating EGFR mutations [5,6]. However, the presence
of intrinsic resistance is an obstacle for lung cancer
treatment. Moreover, despite an initial dramatic re-
sponse to inhibitors, drug resistance to the EGFR-TKI
therapy almost always develops after approximately less
than 1 year from the initiation of the treatment, which
largely reduces the efficacy of these drugs [7]. Therefore,
a better understanding of the molecular mechanisms
underlying lung adenocarcinoma cell proliferation and
apoptosis, as well as their relationship with EGFR-TKIs,
is needed for improving the treatment of lung adenocar-
cinoma more efficiently.
In the past, investigations into the mechanisms of
tumorigenesis mainly focused on protein-coding genes.
Recently, a large number of non-protein-coding tran-
scripts have been discovered. Although once thought to
be a part of the genomic ‘dark matter’, more attention is
now focused on long non-coding RNAs (LncRNAs).
They are distinguished from short RNAs by their length,
which is greater than 200 nucleotides, and have been
shown to regulate many key biological processes [8].
Ewan found several LncRNAs with low expression in
normal tissues but with high expression in both embry-
onic stem and cancer cells [9]. Beyond the expression
changes, accumulating evidence indicates that the aber-
rant expression of some LncRNAs may play an import-
ant functional role in cancer biology [10,11]. Recent
studies have also revealed that LncRNAs can act as
proto-oncogenes (e.g., HOTAIR) or tumor suppressor
genes (e.g., GAS5 (growth arrest-specific transcript 5)) in
tumorigenesis [12,13].
GAS5 is a well-known LncRNA (−650 bases in
humans and encoded at 1q25) that comprises 12 exonsand encodes 10 box C/D snoRNAs within its introns.
GAS5 was originally isolated from NIH 3 T3 cells and is
receiving an increasing level of attention [14,15]. Several
studies found that GAS5 sensitizes cells to apoptosis by
regulating the activity of glucocorticoids in response to
nutrient starvation and induces growth arrest and apop-
tosis independently of other stimuli in some breast can-
cer cell lines. In addition, the GAS5 transcript levels
were found to be significantly reduced in breast and lung
cancer samples compared with adjacent unaffected nor-
mal tissues [12,16].
However, the biological role of GAS5 and its function
in EGFR-TKI-resistant lung adenocarcinoma remain
largely unknown. In the present study, we found that
GAS5 expression was significantly downregulated in
lung adenocarcinoma tissues compared to the adjacent
normal lung tissue, which is of clinical significance. Our
results also showed that GAS5 overexpression reversed
the gefitinib resistance of the human lung adenocarcin-
oma A549 cell line. Our work suggests that GAS5
LncRNA expression may represent a valuable marker for
diagnosis and outcome predictions in patients with lung
adenocarcinoma and that increased GAS5 expression
may overcome the resistance to EGFR-TKIs in resistant
lung adenocarcinoma, both in vitro and in vivo. Taken
together, our results indicate that GAS5 plays an import-
ant role in lung adenocarcinoma development and could
be a potential therapeutic target for lung adenocarcin-
oma patients.Results
GAS5 is downregulated in lung adenocarcinoma tissues
The quantitative reverse-transcriptase polymerase chain
reaction (qRT-PCR) technique was used to assess GAS5
expression in tumor samples and their corresponding
adjacent normal tissues in a total of 99 paired samples.
In cancerous tissues, GAS5 expression was lower than
the average level observed in normal specimens, with an
average expression level of 0.76 compared with normal
tissue (Figure 1A). In eight metastatic lung cancer tis-
sues, GAS5 expression was also lower than that in the
normal specimens, but not significantly (P = 0.087). In
the 19 benign lung tumors, GAS5 expression levels were
slightly lower than in the adjacent normal tissues, with
an average expression level of 0.936 compared with nor-
mal tissues (P = 0.342).
Figure 1 qRT-PCR analysis of LncRNA GAS5 in NSCLC tissues and its clinical significance. GAS5 expression was normalized to GAPDH expression.
(A) GAS5 was measured in 72 pair NSCLC and paired adjacent normal tissues by qRT-PCR. The data are presented as a fold-change in the tumor
tissue relative to the normal tissue. (B) GAS5 expression was significantly lower in the tumors ≥3 cm. (C) GAS5 expression was significantly lower
in moderate-poor differentiation tumors. (D) GAS5 expression was significantly lower in patients with a higher pathological stage. *P < 0.05; **P < 0.01.
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groups: the relatively high-GAS5 group (n = 36, GAS5
expression ratio ≥mean ratio) and the relatively low-
GAS5 group (n = 50, GAS5 expression ratio ≤median ra-
tio). The examination of the correlation between the
clinicopathological features and GAS5 expression levels
showed that decreased GAS5 expression was correlated
with a larger tumor size, poorer differentiation, and
more advanced tumor-node-metastasis (TNM) staging
(Figure 1B–D). However, there was no significant correl-
ation between GAS5 expression and other factors, such
as gender, age, smoking history, lymph node metastasis,
distal metastasis, and carcinoembryonic antigen (CEA),
carbohydrate antigen 19–9 (CA19-9), and cancer antigen
125 (CA125) expression (Table 1).
GAS5 expression and IC50 in four lung adenocarcinoma
cell lines and the characteristics of the cell lines
To screen for the expression of GAS5 in the NSCLC cell
lines, we used qRT-PCR analysis to assess GAS5 expres-
sion in the A549 (K-RAS mutant, EGFR wild-type),
H1299 (EGFR wild-type, N-RAS), H1975 (T790M EGFR
mutant), and HCC827 (EGFR mutant) lung adenocarcin-
oma cell lines. We found that GAS5 was expressed at acomparatively low level in the four lung adenocarcinoma
cell lines compared with the human bronchial epithelial
(HBE) cell line (Figure 2A). We defined the cell lines
with a half maximal inhibitory concentration (IC50) value
higher than 4 μM as gefitinib-resistant [17]. The IC50 of
the A549, H1299, H1975, and HCC827 cell lines were
47.53 ± 3.30 μM, 17.72 ± 0.95 μM, 15.68 ± 0.89 μM, and
0.01 ± 0.001 μM, respectively (Figure 2B). As expected,
the A549 was included in our study as the representative
cell line for innate EGFR-TKI resistance.
GAS5 treatment enhances gefitinib sensitivity in vitro
Because of the significance of LncRNAs in biological
processes, we examined the impact of GAS5 overexpres-
sion on gefitinib resistance in the resistant lung adeno-
carcinoma cell line. GAS5 expression was significant
upregulated 48 h after transfection, and qRT-PCR ana-
lysis showed that GAS5 expression was increased by 68-
fold in A549 cells compared with the control cell line
(Figure 2C).
An MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-
tetrazolium bromide) assay was used to measure the via-
bility of the cells and their IC50 during treatments with
increasing concentrations of gefitinib for 72 h. Compared
Table 1 Clinicopathologic associations of GAS5
expression in lung adenocarcinoma
Clinical parameters No. of cases Relative GAS5 expression
Low High P valuea
Age 0.500
>60 years 39 19 20
≤60 years 33 17 16
Gender 0.479
Male 37 20 17
Female 35 16 19
Smoking 0.151
Non-smoker 42 18 24
Smoker 30 18 12
Differentiation 0.03**
Well 26 14 12
Moderate-Poor 46 36 10
Maximum diameter 0.03**
<3 cm 26 14 12
≥3 cm 46 36 10
Lymphatic metastasis 0.131
Absent 41 27 14
Present 31 25 6
Distal metastasis 1.000
M0 68 34 34
M1 4 2 2
TNM stage 0.047**
I–II 51 32 19
III–IV 21 18 3
CEA 0.583
Positive 34 16 18
Negative 38 18 20
CA19-9 0.500
Positive 39 19 20
Negative 33 17 16
CA125 0.577
Positive 29 16 13
Negative 43 29 24
aChi-squared test. **P < 0.05.
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with GAS5 exhibited a significantly decreased viability
(Figure 2D), and the IC50 of the A549 cell line was de-
creased to 3.665 μM (Table 2).
An EdU (5-ethynyl-2’-deoxyuridine) incorporation
assay was used to detect DNA synthesis, which is an in-
dicator of cell proliferation. As show in Figure 3, the
percentage of EdU-positive cells in the S phase of the
cell cycle was significantly lower in the combinationgroup than in the control and gefitinib alone group (P <
0.05).
In the colony formation assay, we obtained similar re-
sults. The clonogenic survival was greatly decreased fol-
lowing GAS5 overexpression in A549 cells (Figure 4).
Flow cytometry was used to analyze apoptosis in A549
cells exposed to gefitinib for 72 h at a concentration of
4 μM. The cells transfected with GAS5 showed a signifi-
cantly higher apoptosis rate compared with the control
cells (Figure 5).
Collectively, these data revealed that GAS5 could
sensitize the resistant A549 cell line to the cytotoxic ef-
fects of gefitinib.
GAS5 regulates the sensitivity to EGFR-TKIs by inhibiting
IGF-1R
Western blotting analyses were conducted to evaluate
the mechanism behind the enhanced effect of the com-
bined treatment. We assessed the protein expression
levels of EGFR and the activation of its downstream sig-
naling proteins AKT and ERK. In A549 cells, gefitinib or
GAS5 alone minimally inhibited the protein levels of
phospho-EGFR, phospho-ERK, and phospho-Akt. Fur-
thermore, we observed a decrease in the expression of
phospho-EGFR and the downstream signaling proteins
after the combination treatment (gefitinib and GAS5
overexpression) compared with the monotherapy (P <
0.05). In addition, gefitinib combined with GAS5 de-
creased the levels of phospho-ERK and phospho-Akt in
a dose-dependent manner in A549 cells (Figure 6).
The IGF-1R (insulin-like growth factor 1 receptor)
protein level, which has been associated with resistance
to EGFR-TKIs, was also analyzed to explore the potential
mechanisms behind the effects of the GAS5/gefitinib
combination on gefitinib-resistant lung adenocarcinoma
cells. As shown in Figure 6, A549 cells treated with
GAS5 plus gefitinib showed a significant reduction in
the phospho-IGF-IR level. These results indicate that the
tyrosine kinase receptors, which play important roles in
pro-oncogenic signaling in lung adenocarcinoma, were
inactivated and that the cytotoxicity of gefitinib was po-
tentiated by the combined treatment.
GAS5 treatment enhances gefitinib sensitivity in vivo
Although GAS5 can restore sensitivity to gefitinib in
A549 cells, there is little direct evidence for the role of
GAS5 in vivo. A xenograft mouse model was used to
provide further evidence of the role of GAS5 in revers-
ing gefitinib resistance in vivo. Five days after the injec-
tion of empty vector- or GAS5-expressing A549 cells,
detectable tumors developed in both groups. The GAS5
overexpression treatment dramatically decreased the
tumor size and weight compared with the control group
and the gefitinib only group (Figure 7A, C, D). The qRT-
Figure 2 The GAS5 expression in lung adenocarcinoma cell line and the effect of gefitinib combined with GAS5 on the proliferation of A549 cell
line (A) qRT-PCR results demonstrating GAS5 expression in NSCLC cell lines (A549, H1650, H1975, HCC827) compared to human bronchial epithelial
cells (HBEs). (B) IC50 of four NSCLC cell lines. (C) GAS5 expression, measured by qRT-PCR, following the treatment of A549 cell line with pCDNA-GAS5
or empty vector. (D) The effect of GAS5 plus gefitinib on A549 proliferation in vitro. MTT assay was performed to determine the proliferation of
pCDNA-GAS5- or empty vector-transfected A549 cells plus gefitinib.
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of GAS5 in tumors after pcDNA-GAS5 transfection
(Figure 7B). In addition, we monitored the health and
body weight of the mice, which indicated that the mice
tolerated all of the treatments without displaying any
overt signs of toxicity (Figure 7E).
The total proteins were isolated from the A549 xeno-
graft tumors, and western blotting analyses were per-
formed to detect the expression of EGFR and the
activation of its downstream signaling proteins. Our re-
sults revealed that the combined treatment markedly re-
duced the levels of phospho-EGFR and the downstream
signaling proteins phospho-AKT, phospho-ERK, and
phospho-IGF-1R within the tumors (Figure 8). Our re-





Gefitinib Gefitinib + GAS5
A549 46.40 μM 3.665 μM 12.66capable of overcoming the resistance to EGFR inhibitors
in lung adenocarcinoma.Discussion
EGFR is a transmembrane protein with an extracellular
ligand-binding domain and an intracellular domain pos-
sessing an intrinsic tyrosine kinase activity. The overex-
pression of EGFR in NSCLC patients is always
associated with poor prognosis [18]. EGFR-TKIs that tar-
get the tyrosine kinase activity of EGFR have been devel-
oped. However, the limited response rate is an obstacle
to their use for the treatment of NSCLC. Therefore,
overcoming the primary or secondary resistance to
EGFR-TKIs remains one of the most significant chal-
lenges for the successful treatment of lung cancer. To
solve this problem, new strategies have been developed
against EGFR-TKI-resistant cells. However, the combin-
ation of EGFR-TKI treatment with chemotherapeutic
agents caused a significant level of toxicity for the pa-
tients and only achieved a modest increase in survival
[19,20]. Therefore, the identification of alternative
Figure 3 Effects of GAS5 plus gefitinib on cell proliferation in gefitinib-resistant A549 cells. (A) Representative EdU results of four groups. (B)
Effects of GAS5 plus gefitinib on EdU+ stained cells at 6 h after treatment. The data represent the mean ± SD from three independent
experiments. **P < 0.01
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ant NSCLC cells is of critical importance.
Understanding the molecular processes involved in
NSCLC has led to new treatment options. Recently, the
importance of the epigenetic changes that occur during
cancer development was recognized. In total, only 2% of
the human genome is associated with protein-coding
genes and the majority of the human genome is associ-
ated with non-coding RNAs (ncRNAs). An increasing
number of studies show that ncRNAs could play import-
ant regulatory roles in complex organisms [21]. As an
important part of epigenetics, LncRNAs are gaining the
attention of researchers in many fields, and the number
of published articles related to their role in cancer is ex-
ponentially growing [22]. In the present study, our atten-
tion was focused on the GAS5 LncRNA. GAS5 is a
tumor suppressor gene that is downregulated in various
types of cancer [23,24]. The downregulation of GAS5 ex-
pression is thought to contribute to tumor formation
and to affect proliferation and apoptosis [16].Figure 4 A colony-forming growth assay was performed to determine the
plus gefitinib. The colonies were counted and captured. (A) Representative
together synergistically suppress colony formation. The data represent theWe found that the GAS5 expression levels were sig-
nificantly downregulated in lung adenocarcinoma lesions
compared with the adjacent noncancerous tissues, which
was consistent with previous findings in other cancer
types [23,24]. Our current results also show a lower
GAS5 expression in metastatic lung cancer tissues, al-
though this difference was not statistically significant,
possibly because of the limited number of cases ana-
lyzed. More cases of metastatic tissue samples may be
needed to evaluate the relationship between low GAS5
expression and pulmonary metastases. Tumor size and
differentiation status are two key biological features that
determine the aggressiveness of lung adenocarcinoma
tumors and represent the major obstacles to the treat-
ment of these malignancies. The most significant factors
affecting the prognosis of patients with lung adenocar-
cinoma are considered to be the tumor size and the de-
gree of local invasion of the tumor. The potential
relationship between GAS5 levels in tumors and the
clinicopathological features of lung adenocarcinomaproliferation of pCDNA-GAS5- or empty vector-transfected A549 cells
colony formation assay results of four groups. (B) GAS5 and gefitinib
mean ± SD from three independent experiments. **P < 0.01
Figure 5 Flow-cytometric analysis was used to determine the percentage of apoptotic cells. (A) Representative flow-cytometric analysis results of
four groups. (B) A549 cell treated with gefitinib plus GAS5 showed decreased apoptosis. The data represent the mean ± SD from three independent
experiments. **P < 0.01
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expression was associated with a larger tumor size and a
poorer differentiation status. Furthermore, our study is
the first to elucidate the relationship between GAS5 and
benign lung tumors. Indeed, we found that benign lung
tumors display an almost equal GAS5 expression level
as the normal surrounding tissues. This finding supports
the hypothesis that GAS5 acts as a tumor suppressor
gene in lung adenocarcinoma.
To solve the problem of EGFR-TKI resistance, several
new strategies have been developed [17,25]. In addition,
epigenetic therapy has also emerged as a new approach
for cancer treatment. GAS5 can modulate cellularFigure 6 Effect of GAS5 and gefitinib on the activity of the EGFR/PI3K/AKT
and downstream signaling molecules are seen following co-treatment with G
was also seen. (B) Relative levels of P-EGFR, P-AKT, P-ERK and P-IGF-1R protein
independent experiments. *P < 0.05responses by suppressing the glucocorticoid-mediated
induction of several response genes, inducing cell cycle
arrest, inhibiting cell growth, and inducing apoptosis
[26,27]. A recent study has revealed that erlotinib, a
tyrosine kinase inhibitor that acts on the epidermal
growth factor receptor, can significantly affect the ex-
pression of the GAS5 gene in glioma cells [28]. However,
the connection between the GAS5 levels and the sensi-
tivity to EGFR-TKIs in tumor cells is unclear and re-
mains to be elucidated. Here, we explored the effects of
modulating the levels of the GAS5 LncRNA in combin-
ation with gefitinib treatment using in vitro and in vivo
models. We examined the cytotoxicity of a combinationpathway and IGF-1R in A549 cells. (A) Significant suppression of EGFR
AS5 and gefitinib. Dose-dependent downregulation of IGF-1R protein
s expression in six groups. The data represent the mean ± SD from three
Figure 7 GAS5 in combination with gefitinib suppresses the growth of EGFR inhibitor-resistant tumor xenografts in vivo. (A) All the tumors after
removal from the mice after 30 days. (B) qRT-PCR analysis of GAS5 expression in tumor tissues formed from four groups, and qRT-PCR analyses
indicated that GAS5 expression is significantly increased in vivo. (C) Tumor weight when the tumors were harvested. The data represent the
mean ± SD. (D) Tumor growth curve. Six mice per group were used in the xenograft experiment. The tumor volumes of mice were measured.
*P < 0.05, for comparisons with gefitinib alone. (E) The gefitinib treatments did not cause significant body weight loss in the tested mice.
Figure 8 Effect of GAS5 and gefitinib on the activity of the EGFR/PI3K/AKT pathway and IGF-1R in vivo. (A) Significant suppression of EGFR, downstream
signaling molecules, and IGF-1R are seen following co-treatment with GAS5 and gefitinib. (B) Relative levels of P-EGFR, P-AKT, P-ERK, and P-IGF-1R proteins
expression in four groups. The data represent the mean ± SD from three independent experiments. *P< 0.05
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synergistic effect was consistently observed for a number
of parameters, including apoptosis and cytotoxicity.
Compared with gefitinib or GAS5 alone, all of the cells
treated with gefitinib plus GAS5 exhibited a dose-
dependent decrease in viability. Our results suggest that
the gefitinib/GAS5 co-treatment may overcome primary
resistance. However, because GAS5 is known to act as
decoy for the glucocorticoid receptor, we will next inves-
tigate whether glucocorticoid signaling plays a role in
the resistance to EGFR-TKIs and investigate which GR
target genes could be related to the development of
resistance.
EGFR-TKIs can inhibit the downstream effects of the
EGFR pathway, resulting in an inhibition of cell prolifer-
ation, invasion, and survival. Our combined treatment
downregulated EGFR and p-EGFR expression in the
A549 cell line and also resulted in a reduction of both
Akt and ERK phosphorylation. Our results suggest that
GAS5 in combination with gefitinib inhibited EGFR ac-
tivity and the phosphorylation of its downstream path-
way components, which is important to overcome
resistance [29,30], and, finally, restored the sensitivity of
lung adenocarcinoma cell lines to the EGFR-TKIs.
Other studies have found that the overexpression of
IGF-1R was associated with resistance to EGFR-TKI
treatments [31,32]. The Guix’s group study revealed that
treating the EGFR-TKI-resistant A431 cell line with an
IGF-1R inhibitor restored their sensitivity [33]. The
interplay between LncRNAs and proteins is a significant
matter in the field of cancer biology. Previous studies
have shown that the interaction between LncRNAs and
IGF-1R was complicated. Indeed, Aparna et al. found
that the maternal-specific H19-DMR deletion led to the
upregulation of Igf2 and to an increase in IGF-1R trans-
lation, the latter of which is normally suppressed by
H19-derived miR-675 [34]. Patients with squamous cell
carcinoma overexpress IGF-1R more frequently than the
patients with a nonsquamous histology [35]. Therefore,
we hypothesized that GAS5 may also mediate IGF-1R
function to enhance the sensitivity to EGFR-TKIs in lung
adenocarcinoma. Our results demonstrated that GAS5
could directly downregulate IGF-1R expression and, as a
result, decrease cell viability and resistance to EGFR-
TKIs, which suggests that IGF-1R was also a down-
stream target of GAS5 in the resistance to EGFR-TKI.
Zhang et al. [36] showed that miR-21 and GAS5 can
regulate each other in a similar way as the microRNA-
mediated silencing of target mRNAs. Because of the cor-
relation between IGF-1R and Mir-21 [37], we speculate
that GAS5 might downregulate IGF-1R by affecting Mir-
21. In this study, we demonstrated, for the first time,
that GAS5 exerts a tumor suppressive function by regu-
lating IGF-1R expression in lung adenocarcinoma.However, more studies are needed to determine the
pathway that is primarily responsible for the biological
consequences of GAS5 overexpression.
To confirm the importance of GAS5 in gefitinib resist-
ance, we examined whether the overexpression of
LncRNA could affect the gefitinib-induced cytotoxicity
in vivo. These transplanted cells showed a high propen-
sity for invasive growth within the surrounding tissues.
The combined treatment was satisfactory and enhanced
cytotoxicity and tumor suppression. Next, we further
validated our western blotting results in vivo. Our results
revealed a reduction of the phospho-EGFR, phospho-
Akt, phospho-ERK, and phospho-IGF-1R levels in vivo.
Collectively, these results clearly indicate that GAS5 can
overcome EGFR-TKI resistance by inhibiting IGF-1R
in vivo.
In this work, we report, for the first time, that GAS5
downregulation is not only associated with adenocarcin-
oma tumorigenesis and progression but is also associ-
ated with primary resistance to EGFR-TKIs, both
in vitro and in vivo. GAS5 may become a new tool in
our repertoire of anticancer agents for the therapy of
NSCLC. Furthermore, although we identified IGF-1R as
a key downstream mediator of GAS5 in the resistance to
EGFR-TKIs, the underlying molecular mechanisms and
detailed signaling pathways regulating GAS5 remain to
be elucidated. Because GAS5 could be easily detected in
tissue samples, its potential role as an indicator of
EGFR-TKIs’ efficacy and as a target to overcome resist-
ance to EGFR-TKIs requires further in-depth investiga-
tion. Importantly, only wild-type EGFR-expressing cells
were included in our study. Further studies are needed
to explore whether this co-treatment may also overcome
resistance in other contexts.
Conclusion
Our study shows, for the first time, that the upregulation
of GAS5 can overcome the resistance of human adeno-
carcinoma cells to EGFR-TKIs, at least partially by
downregulating IGF-1R. Our results support a potential
therapeutic role for a combinatorial epigenetic platform
for the treatment of lung adenocarcinoma, particularly
in patients with primary EGFR-TKI resistance. Collect-
ively, our study explores the validity of using GAS5 as a
new treatment approach in lung adenocarcinoma. In the
future, the feasibility of this approach should be evaluated
via clinical trials for patients with lung adenocarcinoma.
Materials and methods
Cell lines and cell culture
Human lung adenocarcinoma cell lines (A549, H1299,
H1975, HCC827) and HBE cells were obtained from the
Institute of Biochemistry and Cell Biology of the Chinese
Academy of Sciences (Shanghai, China). The cells were
Dong et al. Journal of Hematology & Oncology  (2015) 8:43 Page 10 of 13cultured in RPMI 1640 medium containing 10% fetal bo-
vine serum (FBS), 100 U/ml of streptomycin, and 2 mM
of L-glutamine under a 5% CO2-containing humidified
atmosphere at 37°C.
Patients and tissue samples
Between February 2013 and June 2014, a total of 72
paired cancerous and matched adjacent noncancerous
lung tissues were collected from lung adenocarcinoma
patients undergoing lobectomy. These patients included
37 men and 35 women, ranging in age from 38 to
75 years, with a median age of 60 years. No patients re-
ceived any preoperative chemotherapy or radiotherapy,
and no patients had a previous history of malignant dis-
ease. Samples from 8 cases of metastatic lung cancer, 19
cases of benign lung tumor, and their corresponding
normal lung tissues were also collected. The 8 metastatic
lung cancer cases included 4 cases of colorectal meta-
static lung cancer, 3 cases of breast metastatic lung can-
cer, and 1 case of renal cell metastatic lung cancer. The
19 cases of benign tumors included 8 cases of inflamma-
tory pseudotumor, 6 cases of tuberculoma, 3 cases of
pulmonary hamartoma, and 2 cases of atypical aden-
omatous hyperplasia (AAH). All of the tumor tissues
were diagnosed histopathologically by at least two
trained pathologists. The clinicopathological characteris-
tics of the included patients with lung adenocarcinoma
are summarized in Table 1, and the characteristics of the
included patients with metastatic lung cancer and be-
nign tumors are shown in Table 3.
After surgery, the resected primary tumors and normal
tissues were immediately frozen in liquid nitrogen and
stored at −80°C until the RNA extraction was per-
formed. The TNM classification and tumor staging were
performed according to the classification criteria of the
World Health Organization and the TNM stage criteria,
as determined by the Union for International Cancer
Control [38].Table 3 GAS5 expression in metastatic lung cancer and benig
No. of cases
Metastatic lung cancer
Colorectal cancer metastases 4
Breast cancer metastases 3





Atypical adenomatous hyperplasia 2
*Two-tailed Student’s t-test.RNA isolation and qRT-PCR analyses
Total RNA was isolated with TRIzol reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s
protocol. The isolated RNA was reverse-transcribed into
cDNA using a reverse transcription kit (Takara, Dalian,
China). The results were normalized against glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) expression.
The PCR primers for GAS5 or GAPDH were as follows:
GAS5 sense, 5’ CCCAAGGAAGGATGAG3’ and reverse,
5’ ACCAGGAGCAGAACCA3’; GAPDH sense, 5’-CAA
TGACCCCTTCATTGACC-3’ and reverse, 5’- TGGAA-
GATGGTGATGGGATT-3’. qRT-PCR data collection
was performed on an ABI 7500 apparatus (Applied Bio-
systems, Foster City, CA, USA). The PCR reaction was
conducted for 2 min at 50°C, 10 min at 95°C, 40 cycles
at 95°C for 15 s, and 60°C for 30 s. The relative quantifica-
tion of GAS5 expression was calculated using the 2−DDCT
method relative to GAPDH levels. All of the qRT-PCR re-
actions were performed in duplicate.
Ethics statement
Written informed consent was obtained from all of the
patients. The study was approved by the Ethics Commit-
tee of the First Hospital of the China Medical University
and was performed in compliance with the Helsinki
Declaration. All of the experiments involving animals
were performed in strict accordance with the recom-
mendations of the Guide for the Care and Use of La-
boratory Animals of the National Institutes of Health.
Construction of the plasmid vector and DNA transfection
Based on the GAS5 sequence available on National Cen-
ter for Biotechnology Information database, the full-
length GAS5 sequence lacking a poly-A tail was synthe-
sized and subcloned into pcDNA3.1 (Jikai, Shanghai,
China). The empty vector or the pcDNA-GAS5 vector
was transfected into A549 cell cultured in six-well plates
using Lipofectamine 2000 (Invitrogen), according to then lung tumor
Relative GAS5 expression
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tor was used as the negative control. The total RNA was
isolated using the TRIzol reagent (Takara, Dalian, China)
48 h after the transfection, and the expression level of
GAS5 was detected by qRT-PCR.
In vitro drug sensitivity and cell viability assay
Gefitinib (Iressa) was purchased from AstraZeneca
(London, England). Cellular proliferation under treat-
ment with various doses of gefitinib after transfection
was quantified using an MTT assay. A549 cells were
seeded in 96-well plates at a density of 5 × 103 cells/well
and incubated overnight at 37°C. The cells were exposed
to serial dilutions of gefitinib (0.01 mM, 0.1 mM, 1 mM,
10 mM, 20 mM, and 40 mM) for 48 h at 37°C. Then,
15 μl of an MTT reagent (0.5 mg/ml in PBS, Sigma St.
Louis, MO, USA) was added into each well. Four hours
later, the medium was replaced with 200 μl of dimethyl
sulfoxide (DMSO, Sigma, St. Louis, MO, USA). The op-
tical density was measured at a wavelength of 570 nm
using a spectrophotometer. The IC50 value was deter-
mined as the concentration at which each drug pro-
duced 50% inhibition of growth, which was estimated
from the relative survival curves and calculated by using
the GraphPad 5 software (Prism). All of the experiments
were performed in triplicate.
Colony formation assay
A549 cells were transfected with pcDNA-GAS5 or the
empty vector and placed onto a fresh six-well plate at a
density of 1 × 104 per well. The cells were maintained in
media containing 10% FBS and exposed to gefitinib at a
concentration of 25 μg/ml for 24 h. Then, the drugs
were washed away and the medium was changed every
3 days for 2 weeks. After 15 days, the colonies were fixed
with methanol and stained with a 0.5% crystal violet so-
lution (Sigma, St. Louis, MO, USA). The colonies that
were larger than 200 μM were manually counted. The
experiments were repeated at least twice.
EdU incorporation assay
Newly synthesized DNA after the indicated treatment in
A549 cells was detected by EdU fluorescence staining
according to the manufacturer’s instructions (Click-iT®
EdU Imaging Kits, Invitrogen). The cells, cultured in a
well of a 24-well plate at a cell density of 30,000 cells
per well, were labeled with 10 μM of EdU and incubated
for an additional 2 h before being fixed with 3.7% for-
maldehyde for 15 min at room temperature. The fixative
was removed and the cells in each well were washed
twice with 1 ml of 3% BSA in PBS. The BSA was re-
moved and 1 ml of 0.5% Triton® X-100 (Sigma, San
Francisco, CA ,USA) in PBS was added to each well and
incubated at room temperature for 20 min. Afterwashing the cells in each well twice with 3% BSA in
PBS, the cells in each well were reacted with 500 μL of
1× Click-iT® reaction cocktail for 30 min at room
temperature in the dark. Subsequently, for nuclear stain-
ing, 1 ml of 1× Hoechst 33342 solution (Sigma, San
Francisco, CA, USA) was added to each well and incu-
bated for 30 min at room temperature in the dark. The
Hoechst 33342 solution was removed and the EdU-
labeled cells were counted using fluorescence micros-
copy (CKX41-F32FL, Olympus, Tokyo, Japan) and nor-
malized to the total number of Hoechst-stained cells.
The Image-Pro Plus software (Version 6.0, Media Cyber-
netics, Bethesda, MD, USA) was used to calculate the
percentage of EdU-positive (EdU+) cells.Flow cytometry analysis of apoptosis
The pcDNA-GAS5- or empty vector-transfected A549
cells were treated with 4 μM of gefitinib and cultured in
six-well plates for 72 h. Then, the cells were harvested
by trypsinization, and apoptosis was evaluated using an
Annexin V-PE/7-AAD Apoptosis Detection Kit (BioVi-
sion, MA, USA). After the double staining with Annexin
V-PE and 7AAD, flow cytometry analysis (FACScan, BD
Biosciences, San Jose, CA, USA) using the CellQuest
software (BD Biosciences) was used to quantify apop-
tosis. The cells were classified into dead cells (Q1), early
apoptotic cells (Q2), viable cells (Q3), and late apoptotic
cells (Q4).Western blotting
The total cellular and tissue protein extracts were sep-
arated on 10% SDS-polyacrylamide gels (SDS-PAGE)
and transferred onto nitrocellulose membranes (Milli-
pore, Bedford, MA, USA). The membranes were
blocked and incubated with primary antibodies over-
night at 4°C. A Bio-Rad protein assay kit was used to
determine the protein concentration. The specific
antibodies for p-EGFR, EGFR, p-AKT, AKT, p-ERK,
ERK, and IGF-1R were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA), and the anti-
bodies for p-IGF-1R and anti-GAPDH were obtained
from Cell Signaling Technology (Beverly, MA, USA).
GAPDH was used as a control. The membranes were
incubated with the appropriate horseradish peroxid-
ase-conjugated monoclonal secondary antibody (Santa
Cruz) at room temperature for 1.5 h. An ECL detec-
tion kit (ThermolBiotech, Boston, MA, USA) was used
to visualize the immunoreactive protein bands. Densi-
tometry (Quantity One Software; Bio-Rad, Hercules,
CA, USA) analysis was used to quantify the relative
levels of protein expression. The experiments were re-
peated three times.
Dong et al. Journal of Hematology & Oncology  (2015) 8:43 Page 12 of 13In vivo chemosensitivity assay
Six-week-old female BALB/c nude mice were used for
the tumor formation assay. The mice were housed in an
animal facility with a controlled environment, main-
tained at a temperature of 23 ± 2°C, 60 ± 5% humidity,
under a 12:12 h light:dark cycle, with ad libitum access
to sterilized food and water. A549 cells were transfected
with pcDNA-GAS5 or empty vector and harvested from
six-well culture plates after 48 h. Then, the cells were re-
suspended in a 50% RGF matrigel (BD Biosciences) solu-
tion in PBS at a concentration of 2 × 107 cells/ml and
injected in the right flank of the mice in a 100-μl vol-
ume. All of the mice were treated with gefitinib at
100 mg/Kg/day. The tumors were measured every 5 days
using calipers. The tumors were resected from all of the
mice after 30 days, and the subcutaneous growth of each
tumor was calculated using the equation V = 0.5 ×D × d2
(V, tumor volume; D, tumor length; d, tumor width). All
of the procedures were performed under sodium pento-
barbital anesthesia, and all measurements were acquired
in a manner that minimizes suffering.Serological tumor marker analysis
The levels of serum CEA, CA19-9, and CA125 were
measured using an Elecsys 2010 machine (Roche Diag-
nostics, Basel, Switzerland). The cutoff values were
4.3 ng/ ml, 27 U/ml, and 35U/ml for CEA, CA19-9, and
CA125, respectively.Statistical analyses
All statistical analyses were performed using the SPSS
version 18 software (Chicago, IL, USA). Two-tailed Stu-
dent’s t-test, one-way ANOVA, and chi-square test were
used to analyze the data. The values were expressed as
the means ± standard deviations. Values of P ≤ 0.05 were
considered statistically significant.
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